Revelation Biosciences Inc. to Present at the 34th Annual Roth Conference James PhillipsMarch 8, 2022
Revelation Biosciences Inc. to Present at 2022 BIO CEO & Investor Conference James PhillipsFebruary 7, 2022
Revelation Biosciences Inc. Announces First Group of Patients Dosed in Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx-99 for the Prevention of H3N2 Influenza Infection James PhillipsJanuary 20, 2022
Revelation Biosciences Inc. Announces First Patient Enrolled and Dosed in Phase 1b Clinical Study of REVTx-99 for the Treatment of Allergic Rhinitis James PhillipsJanuary 18, 2022
Revelation Biosciences Inc. Announces Data Demonstrating REVTx-99 In Vitro Anti-Viral Activity Against SARS-CoV-2; Commencement of Trading as a Public Company James PhillipsJanuary 11, 2022
Petra Acquisition, Inc. Announces Share Redemption Backstop and Forward Purchase Agreements in Connection with Revelation Biosciences, Inc. Business Combination James PhillipsDecember 22, 2021
Petra Acquisition, Inc. Announces Special Meeting of Stockholders to Approve Business Combination with Revelation Biosciences, Inc. James PhillipsDecember 16, 2021
Revelation Biosciences Inc. Announces Initiation of a Phase 2b Study to Assess Efficacy of Intranasal REVTx-99 for The Prevention of H3N2 Influenza James PhillipsDecember 1, 2021
Revelation Biosciences Inc. Announces Creation and Appointments to Scientific Advisory Board James PhillipsNovember 29, 2021
Revelation Biosciences Inc. Announces Initiation of a Phase 1b Clinical Study of REVTx-99 for the Experimental Treatment of Allergic Rhinitis and Chronic Nasal Congestion James PhillipsNovember 15, 2021
Revelation Biosciences Inc. Engages Partnering Advisor, MedWorld Advisors, to Optimize Value of the Company’s Diagnostic Tool, REVID James PhillipsNovember 1, 2021
Revelation Biosciences Inc. Engages Destum Partners Inc. to Identify a Strategic Partners for REVTx-99 (Ex-US) and REVTx-200 (Worldwide) James PhillipsOctober 25, 2021
Revelation Biosciences Inc. Receives Approval to Begin a Phase 1b Clinical Study of REVTx-99 as an Experimental Treatment for Allergic Rhinitis and Chronic Nasal Congestion James PhillipsOctober 4, 2021
Revelation Biosciences Inc. Receives Approval to Initiate Phase 2b Viral Challenge Study of REVTx-99, an Experimental Prophylactic Treatment for the Prevention of Respiratory Viral Infections James PhillipsSeptember 28, 2021
Revelation Biosciences a Life Sci. Co. Developing Therapeutics & Diag. for Respiratory Viral Infections Including COVID-19 to Become Publicly Traded through a Merger with Petra Acquisition Inc James PhillipsAugust 30, 2021
Revelation Biosciences Inc. Announces Results of Phase 1 Clinical Study of REVTx‑99, an Experimental Therapy for the Prevention of Respiratory Viral Infection James PhillipsMay 5, 2021
Revelation Biosciences Inc. to Present at BIO CEO & Investor Digital Conference James PhillipsFebruary 11, 2021
Revelation Biosciences Inc. Completes Dosing of Five Single Dose Cohorts and Receives Approval to Initiate a Multiple Dose Cohort to Phase 1 Clinical Study of REVTx‑99 James PhillipsFebruary 3, 2021
